A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Genmab
Takeda
Hoffmann-La Roche
Prescient Therapeutics, Ltd.
Regeneron Pharmaceuticals
Shanghai Pharmaceuticals Holding Co., Ltd
Cellectar Biosciences, Inc.
Gilead Sciences
Celgene
Allogene Therapeutics
AstraZeneca
Merck Sharp & Dohme LLC
Pfizer
Daiichi Sankyo
Pfizer
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Shanghai Miracogen Inc.
Chengdu Zenitar Biomedical Technology Co., Ltd
Haihe Biopharma Co., Ltd.
Acerta Pharma BV
Shandong New Time Pharmaceutical Co., LTD
CytomX Therapeutics
Gilead Sciences
Beijing InnoCare Pharma Tech Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Aadi Bioscience, Inc.
Celgene
Merck Sharp & Dohme LLC
Novartis
GlaxoSmithKline
Merck Sharp & Dohme LLC
Ryvu Therapeutics SA
Ryvu Therapeutics SA
Qilu Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals
Amgen
Incyte Corporation
Affimed GmbH
Juventas Cell Therapy Ltd.
AbbVie
Jiangsu HengRui Medicine Co., Ltd.
Incyte Corporation
Shenyang Sunshine Pharmaceutical Co., LTD.
Istari Oncology, Inc.
Shanghai Miracogen Inc.
Celgene
Rapa Therapeutics LLC
CARGO Therapeutics
Faeth Therapeutics